We are live on ! Find out more
IRWD icon

Ironwood Pharmaceuticals
IRWD

149 hedge funds and large institutions have $2.35B invested in Ironwood Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 38 increasing their positions, 57 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

144% more call options, than puts

Call options by funds: $17M | Put options by funds: $6.95M

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

3% more capital invested

Capital invested by funds: $2.29B → $2.35B (+$59M)

1.95% less ownership

Funds ownership: 134.79% → 132.84% (-1.9%)

6% less funds holding

Funds holding: 158 → 149 (-9)

20% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 25

33% less repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 57

Holders
149
Holders Change
-9
Holders Change %
-5.7%
% of All Funds
3.42%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
20
Increased
38
Reduced
57
Closed
25
Calls
$17M
Puts
$6.95M
Net Calls
+$10M
Net Calls Change
+$1.13M

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$82.5M
2
O
OppenheimerFunds
New York
+$38.5M
3
SCM
Sarissa Capital Management
Connecticut
+$25.6M
4
State Street
State Street
Massachusetts
+$17.9M
5
Capital World Investors
Capital World Investors
California
+$10.4M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$84.1M
2
O
OrbiMed
New York
-$23.7M
3
Norges Bank
Norges Bank
Norway
-$20M
4
RCAMU
Rothschild & Co Asset Management US
Connecticut
-$18.4M
5
SAM
Senzar Asset Management
New York
-$11.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
RSCM
151
Rock Springs Capital Management
Maryland
– -$3.37M -268,650 Closed
Thrivent Financial for Lutherans
152
Thrivent Financial for Lutherans
Minnesota
– -$2.57M -204,635 Closed
CIA
153
Capital Impact Advisors
Massachusetts
– -$1.4M -111,449 Closed
Ameriprise
154
Ameriprise
Minnesota
– -$1.13M -89,671 Closed
WMSA
155
Weiss Multi-Strategy Advisers
New York
– -$899K -71,640 Closed
Macquarie Group
156
Macquarie Group
Australia
– -$886K -70,599 Closed
AIM
157
Alambic Investment Management
California
– -$867K -69,074 Closed
VRS
158
Virginia Retirement Systems
Virginia
– -$531K -42,268 Closed
SCA
159
Secor Capital Advisors
New York
– -$499K -39,764 Closed
CSS
160
Cubist Systematic Strategies
Connecticut
– -$465K -37,010 Closed
JG
161
Jefferies Group
New York
– -$442K -35,237 Closed
Millennium Management
162
Millennium Management
New York
– -$367K -29,211 Closed
DIA
163
Denver Investment Advisors
Colorado
– -$319K -25,427 Closed
Squarepoint
164
Squarepoint
New York
– -$269K -21,451 Closed
DTL
165
Dynamic Technology Lab
Singapore
– -$204K -16,240 Closed
AQR Capital Management
166
AQR Capital Management
Connecticut
– -$201K -15,986 Closed
Susquehanna International Group
167
Susquehanna International Group
Pennsylvania
– -$187K -15,024 Closed
II
168
Inspire Investing
Idaho
– -$52K -4,131 Closed
Pacer Advisors
169
Pacer Advisors
Pennsylvania
– -$44K -3,501 Closed
Envestnet Asset Management
170
Envestnet Asset Management
Illinois
– -$14K -1,077 Closed
FANJ
171
Financial Architects (New Jersey)
New Jersey
– -$8.19K -657 Closed
STA
172
Summit Trail Advisors
New York
– -$8K -653 Closed
TRCT
173
Tower Research Capital (TRC)
New York
– -$7K -596 Closed
DCM
174
Delpha Capital Management
New York
– -$1K -113 Closed
3 4 5 6
7

IRWD Hedge Fund Activity: Q1 2018 in Review

149 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q1 2018, worth a combined $2.35B — up 2.6% from $2.29B a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of IRWD and 20 opened new positions — a net loss of 5 holders — while 57 trimmed existing stakes and 38 added.

The largest buyer was BVF Inc, opening a new position worth an estimated $82.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $84.1M.

  • 149 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q1 2018, down from 158 in Q4 2017.
  • Funds reported $2.35B of Ironwood Pharmaceuticals stock for Q1 2018, up 2.6% quarter-over-quarter.
  • 20 funds opened new Ironwood Pharmaceuticals positions in Q1 2018 and 25 closed out, a net change of -5 holders.
  • The largest Ironwood Pharmaceuticals buyer in Q1 2018 was BVF Inc, an estimated $82.5M added.
  • The largest Ironwood Pharmaceuticals seller in Q1 2018 was T. Rowe Price Associates, an estimated $84.1M sold.

Based on aggregated 13F filings for Q1 2018.